September 12, 2022
Xiromed LLC Launches Fulvestrant Injection 250 mg/5 mL (50 mg/mL)

Florham Park, NJ, September 12th, 2022

Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced
the launch of Fulvestrant Injection 250 mg/5 mL (50 mg/mL), generic to Faslodex®.

Annual market sales for Faslodex® and its generics for the twelve-month period ending July,
2022 were $101.4 million, according to IQVIA™.

Rob Spina, CEO of Xiromed commented, “The launch of Fulvestrant injection
demonstrates Xiromed’s ability to leverage Insud Pharmaceutical’s breadth of manufacturing
capabilities to bring high-quality, vertically integrated generic products to the US market. Our
fulvestrant pre-filled syringe product is manufactured at Insud’s dedicated hormonal injectable facility,
Laboratorios Farmalan, located in Leon, Spain and the fulvestrant active pharmaceutical ingredient is
manufactured at our API facility, Industriale Chimica in Saronno, Italy. Xiromed is committed to
expanding our portfolio of hormonal injectable products.”

Xiromed LLC, located in Florham Park, NJ, is the US generic division of Insud Pharma, S.L., a
global pharmaceutical group headquartered in Madrid, Spain. Xiromed is focused on developing and
commercializing high quality generic pharmaceutical products for the US market. In addition to its
commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of
generic pharmaceutical products in various stages of development, including injectable, inhalation and
complex generic products. Learn more at